Hi, Nov 2022: Post-procedural outcomes…. report; No moderate or severe paravalvular leak.
This versus the Abbot device; ‘… to reduce or eliminate paravalvular leak. This seems to be a little too vague, imo.
Perhaps as somebody has suggested ‘one’ person could contact the company to clarify if there are actual figures to compare the two and then share.
Would seem to suggest (the FDA app) that this puts Abbot out of the running for interest in Anteris.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$5.98 |
Change
-0.140(2.29%) |
Mkt cap ! $92.68M | |||
| Open | High | Low | Value | Volume |
| $6.01 | $6.08 | $5.95 | $28.28K | 4.712K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 500 | $5.95 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $6.07 | 2710 | 2 |
View Market Depth
| Last trade - 13.16pm 26/06/2025 (20 minute delay) ? |
| AVR (ASX) Chart |